Teriflunomide
- Generic Name
- Teriflunomide
- Brand Names
- Aubagio, Teriflunomide Accord, Teriflunomide Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 163451-81-8
- Unique Ingredient Identifier
- 1C058IKG3B
- Background
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patie...
- Indication
Used in the treatment of relapsing forms of multiple sclerosis (MS).
- Associated Conditions
- Multiple Sclerosis
- Associated Therapies
- -
Relationship Between Oral DMT Burden and Adherence in MS
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Monash University
- Target Recruit Count
- 323
- Registration Number
- NCT04676204
- Locations
- 🇦🇺
Monash University, Melbourne, Victoria, Australia
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 746
- Registration Number
- NCT04586010
- Locations
- 🇺🇸
Johns Hopkins University School Of Medicine; Outpatient Center, Baltimore, Maryland, United States
🇺🇸OhioHealth, Columbus, Ohio, United States
🇺🇸The Boster Center for MS, Columbus, Ohio, United States
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 751
- Registration Number
- NCT04586023
- Locations
- 🇦🇹
Kepler Universitätskliniken GmbH - Med Campus III; Neurologie & Psychiatrie, Linz, Austria
🇦🇹Medizinische Universität Wien; Univ.Klinik fuer Neurologie, Wien, Austria
🇧🇷L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, Brazil
Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 82
- Registration Number
- NCT04410965
- Locations
- 🇨🇳
Investigational Site Number, China, China
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1124
- Registration Number
- NCT04338022
- Locations
- 🇺🇸
Research Site 612, Farmington Hills, Michigan, United States
🇦🇹Research Site 151, Innsbruck, Austria
🇦🇹Research Site 153, Vienna, Austria
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1124
- Registration Number
- NCT04338061
- Locations
- 🇺🇸
Research Site 736, Asheville, North Carolina, United States
🇺🇸Research Site 748, Philadelphia, Pennsylvania, United States
🇺🇸Research Site 719, Sarasota, Florida, United States
Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Biocad
- Target Recruit Count
- 270
- Registration Number
- NCT04056897
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of Nizhny Novgorod region "Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod", Nizhny Novgorod, Russian Federation
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- McGill University
- Target Recruit Count
- 24
- Registration Number
- NCT03561402
- Locations
- 🇨🇦
Department of Pathology, Montréal, Quebec, Canada
Teriflunomide Tecfidera LMCE
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 120
- Registration Number
- NCT03526224
- Locations
- 🇺🇸
Buffalo Neuroimaging Analysis Center, Buffalo, New York, United States
Mechanistic Studies of Teriflunomide in RRMS
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 30
- Registration Number
- NCT03464448
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.